Another great article from https://blog.cytoplan.co.uk
Curcumin, an active constituent of the root of the perennial herb turmeric (also known as Curcuma longa) and a member of the ginger (Zingiberaceae) family, has been used in India and the Far East for thousands of years as a culinary spice and a medicinal herb.
In the last couple of decades, there has been an explosion in scientific interest and research around curcumin’s potential as a natural therapeutic agent for a wide range of chronic inflammatory health conditions. A search on PubMed for curcumin in the title/abstract gives nearly 12,000 search results – much of this research is in vitro or using animal models to demonstrate mechanisms and pathways.
The US website www.clinicaltrials.gov lists 183 clinical trials using curcumin; of which 64 are still underway.
In this article, we review the properties and molecular targets of curcumin, recent improvements to the technology available to address the problem of curcumin’s poor bioavailability and absorption, and noteworthy clinical trials.
Curcumin was first isolated in 1815, and its chemical structure and synthesis were confirmed in 1910 and 1913. Turmeric is used as a culinary spice and provides curry with its distinctive orange-yellow colour. It is also commonly used as a colouring agent in cheese, butter and cosmetics.
In Ayurvedic medicine (the Indian system of holistic medicine) and traditional Chinese medicine, it has been used for gynaecological problems, gastric problems, hepatic disorders, skin conditions, stress, depression, infectious diseases, and blood disorders. In ancient Hindu medicine, it was used to treat sprains and swelling. Topically, turmeric is used for analgesia, ringworm, bruising, eye infections, inflammatory skin conditions, inflammation of the oral mucosa and infected wounds. Throughout the Orient, it has traditionally been used as an anti-inflammatory, and many of its therapeutic effects are being researched and confirmed by modern scientific research.
Curcumin has antimicrobial, antioxidant, anti-inflammatory and liver detoxification properties. Goel Et-al. (2008) 5 list some molecular targets for curcumin including gene transcription factors, inflammatory cytokines, enzymes, growth factors, receptors and others.
When curcumin is co-administered with piperine, which increases intestinal absorption and reduces enterohepatic metabolism, bioavailability is increased; in one study serum levels of curcumin increased by 2000%.
However, piperine may be a problem for some individuals as it may alter drug metabolism and influence intestinal permeability.
When turmeric/curcumin is heated gently and dissolved in oil (as in traditional Indian cooking), it bypasses intestinal enzymes and can be directly absorbed into chylomicrons and then the lymphatic system, thus bypassing the liver. Based on this knowledge, other delivery platforms to improve absorption have now been developed, e.g. liposomal, phospholipid or optimised formulations.
Longvida® Optimised Curcumin is an innovative, more bioavailable form of curcumin. The patented SLCP™ (Solid Lipid Curcumin Particle) technology behind Longvida® renders the curcumin highly permeable, soluble, and stable. It was developed by neuroscientists in the U.S. and is one of the only curcumin supplement ingredients to undergo systematic “gold-standard” randomised controlled trials for both efficacy and safety; scientifically proven to be 67-285 times more bioavailable than standard 95% curcumin depending on cMAX, AUC, and AUC normalised calculations.
Longvida® provides therapeutic levels of free, active (not deactivated/metabolised or glucuronidated) curcumin and delivers free curcumin into the bloodstream and target tissues (including across the blood-brain barrier and blood-retinal barrier) for a full 24 hours of circulation and hence biological action. The SLCP™ encapsulation technology protects the curcumin from the harsh environment of the stomach and from being quickly broken down and excreted from the body. Longvida® is free of piperine, harsh solvents and volatile oils.
In vitro and in vivo studies indicate curcumin may be a therapeutic agent in many chronic diseases such as autoimmune, cardiovascular, inflammatory bowel, neurological and psychological diseases. There is also interest in the use of curcumin in cancer prevention and alongside chemotherapy. Success in some of the reported clinical trials to-date has been limited due to issues with bioavailability and absorption when administered as an extract.
Rheumatoid arthritis: A clinical trial compared the effects of curcumin with the anti-rheumatic drug, phenylbutazone. The 18 patients in the trial received a daily dose of either curcumin or phenylbutazone for two weeks. Curcumin was well tolerated, had no side effects, and exerted an anti-rheumatic activity comparable to that of phenylbutazone.
In another study of 45 patients, curcumin (500 mg) and diclofenac sodium (50 mg) was administered alone or together to 3 groups of patients with RA. The curcumin group showed the highest percentage of improvement in Disease Activity Score (DAS), and American College of Rheumatology (ACR) criteria for reduction in tenderness and swelling of joints and these scores were significantly better than the patients in the diclofenac sodium group.
Osteoarthritis: In a clinical trial with 22 patients curcumin significantly reduced cartilage matrix degradation markers, reduced CRP, and there was an improvement in the ‘global assessment of disease activity’ in the patients.
In a larger trial of 367 patients, curcumin was as effective as ibuprofen in relieving pain and stiffness and improving function after four weeks of treatment.
Hanai Et-al. (2006) investigated curcumin in patients with quiescent ulcerative colitis. The trial involved 89 patients and concluded that curcumin “seems to be a promising and safe medication for maintaining remission in patients with quiescent ulcerative colitis.”
In another pilot study of 5 patients with Crohn’s and 5 with ulcerative proctitis, all the proctitis patients improved and 4 reduced their medication. Of the Crohn’s disease patients, 4 of 5 had lowered Crohn’s Disease Activity Index scores.
An eight week trial with 32 postmenopausal women compared the effectiveness of curcumin and exercise in improving vascular function. The researchers concluded “curcumin is as effective in improving vascular function in postmenopausal women as a moderate aerobic exercise training programme.
Currently, there are more than a dozen published independent clinical studies behind Longvida® curcumin’s anti-inflammatory and anti-oxidant properties which have been studied for various health applications including:
In a recent randomised, double-blind, placebo-controlled trial people from a healthy older population reported improved cognitive function and mood improvement using 400mg Longvida®.
A 2016 study conducted at the University of North Texas was published on Longvida®’s ability to reduce inflammatory and muscle damage biomarkers following oral supplementation. After exercise-induced muscle damage, subjects showed significantly smaller increases in key inflammatory biomarkers (such as inflammatory cytokines) with the administration of 400mg/day versus placebo.
Longvida® improved endothelial-dependent dilation (EDD) of blood vessels after 12 weeks in middle-aged and older adults mediated, in part, by an increase in nitric oxide bioavailability, reduction in oxidative stress and inflammatory signalling.
A 2012 study published in Nutrition Journal demonstrated that one small, single daily dose of Longvida® offered significant health benefits (including lowered plasma triglyceride values and increased plasma nitric oxide) in healthy middle-aged people in just 30 days.
Areas of ongoing research include muscle repair, cardiovascular health, joint health, sports nutrition, eye health, cancer prevention, cognition/mood and brain health.
Curcumin has multiple molecular targets, and many mechanisms of its action are now understood thanks to in vitro and animal models. Clinical trials were initially hampered by its low bioavailability. This has now been improved by liposomal or optimised formulations such as Longvida® Optimised Curcumin. Curcumin continues to be an exciting area of on-going clinical research.
Curcumin is an active component of the root of the perennial herb turmeric (also known as Curcuma longa), it has been used in India (and other parts of the Far East) for thousands of years as a culinary spice and a medicinal herb.
Recent scientific research has demonstrated that curcumin has antimicrobial, antioxidant, anti-inflammatory and liver detoxification properties.
Curcumin is considered to have a low systemic bioavailability resulting in low plasma and tissue levels.
Delivery platforms to improve the poor bioavailability of curcumin have now been developed, e.g. liposomal, phospholipid or optimised formulations.
In vitro and in vivo studies indicate curcumin may be a therapeutic agent in many chronic diseases such as autoimmune, cardiovascular, inflammatory bowel, neurological and psychological diseases.
Curcumin continues to be the focus of significant scientific interest with many on-going trials.